Short Interest in Sino Biopharmaceutical (OTCMKTS:SBMFF) Drops By 30.6%

Sino Biopharmaceutical (OTCMKTS:SBMFF) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 34,229,400 shares, a decline of 30.6% from the August 31st total of 49,345,500 shares. Based on an average daily volume of 900 shares, the short-interest ratio is currently 38,032.7 days. Based on an average daily volume of 900 shares, the short-interest ratio is currently 38,032.7 days.

Sino Biopharmaceutical Stock Down 2.1%

Shares of SBMFF stock opened at $1.07 on Tuesday. Sino Biopharmaceutical has a 52 week low of $0.37 and a 52 week high of $1.24. The company has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $0.74.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.